nocturnal

Iptacopan hydrochloride (LNP023 hydrochloride) is an orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 of 10 nM. Iptacopan hydrochloride shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM.

Famotidine (MK-208) is a propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors on the basolateral membrane of parietal cells, famotidine reduces basal and nocturnal gastric acid secretion, thereby decreasing gastric volume, acidity, and the amount of gastric acid released in response to various stimuli.

1,2-Dimethoxybenzene, a natural product secreted by Silene latifolia, is an effective pollinator for the nocturnal moth Hadena bicruris.

Factor B-IN-7 (Compound (I)) is a selective inhibitor of Factor B. It disrupts the interaction between Factor B and C3b, thereby preventing excessive complement activation. Factor B-IN-7 holds potential for research into complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy, and age-related macular degeneration (AMD).

Factor B-IN-8 (Compound (3R,4R)-15) is a potent, selective, and orally active inhibitor of Factor B, demonstrating an IC50 value of 10.2 nM. It effectively blocks the interaction between Factor B and C3b, thus preventing the formation of the C3 convertase (C3bBb). Additionally, Factor B-IN-8 hinders the deposition of the membrane attack complex (MAC) along the alternative pathway with an IC50 of 59.3 nM. This compound reduces the cleavage of Factor B protein and lessens the deposition of complement C3d in the glomeruli and renal tubules. Factor B-IN-8 is applicable in the research of arthritis and paroxysmal nocturnal hemoglobinuria (PNH).

AGN-201904Z is a slowly absorbed, acid-stable pro-proton pump inhibitor (pro-PPI) rapidly converted to omeprazole in the systemic circulation giving a prolonged residence time. AGN 201904-Z produced a significantly greater, and nocturnal acid suppression

Desmopressin (DDAVP)(DDAVP) is the synthetic analogue of the antidiuretic hormone arginine vasopressin.Vasopressin Receptor The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. Desmopressin works by limiting the amount of water that is eliminated in the urine. Desmopressin binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates release of von Willebrand factor from endothelial cells by acting on the V2 receptor.

Desmopressin acetate (16679-58-6 free base) (DDAVP) is the synthetic analog of the antidiuretic hormone arginine vasopressin. Vasopressin Receptor The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. Desmopressin acetate (16679-58-6 free base) works by limiting the amount of water that is eliminated in the urine. Desmopressin acetate (16679-58-6 free base) binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates the release of von Willebrand factor from endothelial cells by acting on the V2 receptor.

Lupitidine hydrochloride inhibits nocturnal acid secretion.

Cisapride tartrate is chemically related to metoclopramide, but unlike metoclopramide, it does not cross the blood-brain barrier or have antidopaminergic effects. Cisapride is a serotonin-4 (5-HT4) receptor agonist. Cisapride was indicated for the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease. The Food and Drug Administration (FDA) in America stopped the marketing of cisapride as of 14th July 2000. They had received at least 341 reports of heart rhythm abnormalities and these led to 80 deaths. Other reported adverse effects are: headache, diarrhea, abdominal pain, nausea, constipation. Cisapride for animals has been found helpful in some cases of megaesophagus and is a common treatment for feline megacolon. Clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride. Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be e......

Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation. It can be used for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.

Crovalimab (SKY59; RO7112689) is an Fc-engineered and pH-dependent humanised monoclonal antibody that binds to complement C5 and blocks its cleavage into C5a and C5b, thereby inhibiting MAC formation and intravascular haemolysis. It can rebind to the FcRn receptor under acidic pH conditions and return to the bloodstream, making it suitable for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

Danicopan (ACH-4471) (ACH-4471) is a selective, orally active small molecule factor D inhibitor with high binding affinity to human factor D, with a Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits the activity of the complement replacement pathway (APC) and may block the complement replacement pathway in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

Famotidine (Standard) is the standard substance of Famotidine, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Famotidine (MK-208) is a propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.

NNC0165-1273 is a peptide YY (PYY3-36) analogue acting as an intestinal hormone. It shows significantly higher affinity for the Y2 receptor compared to the Y1, Y4, and Y5 receptors. NNC0165-1273 effectively induces anorexia and decreases food intake prompted by nocturnal and ghrelin stimulation through increased satiety. It also inhibits the expression of cFos in NPY/AgRP neurons induced by ghrelin. NNC0165-1273 is applicable in anti-obesity therapy research.

NNC0165-1273(TFA) is the trifluoroacetate salt form of NNC0165-1273. It is an analog of the gut hormone peptide YY (PYY3-36). The compound shows a significantly higher affinity for the Y2 receptor compared to Y1, Y4, and Y5 receptors. NNC0165-1273 exhibits potent anorectic effects, significantly reducing nocturnal and ghrelin-induced food intake by promoting early satiety. It also inhibits cFos expression in NPY/AgRP neurons induced by ghrelin. NNC0165-1273 can be utilized in research focused on anti-obesity therapies.